Clinical Trials on Multidrug-resistant Gram-negative Bacteria Infection in Finland

Total 121 results

Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
Helsinki University Central Hospital

Unknown

Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines (Ty21a-ASC)

Healthy

Finland
Pfizer

Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

Infections, Meningococcal

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Meningococcal Infections

Finland
Tampere University

Completed

Helicobacter Pylori and Acute Alcohol Induced Pancreatitis

Helicobacter Infections | Pancreatitis, Acute

Finland
GlaxoSmithKline

Completed

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Tetanus | Diphtheria | Acellular Pertussis

Finland
Helsinki University Central Hospital
University of Helsinki

Recruiting

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Cholera | Typhoid Fever | Vaccine-Preventable Diseases

Finland
University of Turku
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

EUpertstrain 4 Study of Bordetella Pertussis Isolates

Bordetella Pertussis, Whooping Cough

Finland
Pfizer

Completed

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Meningococcal Infection

United States, Finland, Czechia, Sweden, Denmark, Germany
Turku University Hospital
Helsinki University Central Hospital; Satakunta Central Hospital; Päijät-Häme...

Recruiting

FMT in Initial CDI (FinCDI)

Clostridioides Difficile Infection

Finland
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Pfizer

Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

Infections, Meningococcal

Finland
Turku University Hospital

Completed

Study of Lyme Neuroborreliosis

Lyme Neuroborreliosis

Finland
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
University of Oxford
University of Turku; National Institute for Public Health and the Environment...

Completed

A Study Exploring Whooping Cough Protection in Children and Adults (BERT)

Pertussis

United Kingdom, Finland, Netherlands
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

Meningococcal Meningitis

Finland, Poland
T2 Biosystems

Terminated

Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

Lyme Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
GlaxoSmithKline

Completed

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Infections, Meningococcal

United States, Finland, Poland
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Healthy Volunteers | Meningococcal Immunisation

Spain, Finland, Germany, Hungary
The Miriam Hospital

Unknown

Gut Microbiota Changes After Fecal Microbiota Transplantation

Clostridium Difficile Infection

United States
University of Helsinki

Completed

Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia (FINLEVO)

Sepsis | Bacteremia | Staphylococcus Aureus | Endocarditis

Finland
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Infections, Meningococcal

Finland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
Arto Palmu
GlaxoSmithKline

Completed

Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage (FinIPcarr)

Pneumococcal Infections

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Meningococcal Infections

Czechia, Finland, Italy, Poland, Romania, Spain, Sweden
Novartis Vaccines

Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Meningococcal Disease

Austria, Finland, Germany, Italy, Czech Republic
Quidel Corporation

Completed

Sofia 2 Lyme FIA Whole Blood Clinical Study

Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans)

United States
Pfizer
Valneva Austria GmbH

Active, not recruiting

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Lyme Borreliosis

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Infections, Meningococcal

United States, Australia, Finland, Poland, Belgium, Brazil, Sweden, Turkey
Pfizer

Completed

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

Lyme Borreliosis

United States, Germany, Belgium
Advanced Laboratory Services, Inc.

Terminated

A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease (ALSIBDT)

Lyme Disease

United States
Aeras
Statens Serum Institut

Completed

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

Tuberculosis

Finland
University of Prince Edward Island
The Queen Elizabeth Hospital

Completed

The Feasibility of Pertussis Immunization in a Canadian Emergency Department

Pertussis

Canada
Kent Hospital, Rhode Island
National Institute of General Medical Sciences (NIGMS)

Active, not recruiting

Improving Rhode Island's Tuberculosis Preventive Services in Primary Care

Latent Tuberculosis

United States
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

Lyme Disease

United States
Novartis Vaccines

Completed

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Meningococcal Infections

Canada, United States
Northwell Health
Staten Island University Hospital

Completed

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?

Tuberculosis

United States
Pfizer
Valneva Austria GmbH

Active, not recruiting

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) (VALOR)

Lyme Disease

United States, Finland, Canada, Poland, Sweden, Germany, Netherlands
NICHD Neonatal Research Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Early-Onset Sepsis Surveillance Study (EOS)

Sepsis | Gram-Negative Bacterial Infections | Gram-Positive Bacterial Infections | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, Newborn

United States
Microbiome Health Research Institute
Brown University; Tufts Medical Center; Indiana University; Edward Hospital

Terminated

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection (STOOL)

Clostridium Difficile

United States
GlaxoSmithKline

Completed

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

Infections, Meningococcal

United States, Australia, Finland, Estonia, Canada, Turkey, Czechia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland, Germany, Hungary, Spain
Oxford Immunotec

Terminated

Lyme Test Indication Combinations (LyTIC) Study (LyTIC)

Lyme Disease

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population

Infections, Streptococcal

Belgium, Sweden, Finland
Finnish Institute for Health and Welfare
Turku University Hospital; GlaxoSmithKline

Completed

Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10

Pneumococcal Infections

Finland

3

Subscribe